Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
<< Back to Results
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or lymph nodes or has spread to other places in the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sorafenib tosylate together with doxorubicin hydrochloride is more effective than sorafenib tosylate alone in treating liver cancer.
https://www.clinicaltrials.gov/ct2/show/NCT01015833
Location:
Essentia Health Duluth
Disclosures:
None
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.
